CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04542291
NCT04542291Phase 1Completed
CompareCT.gov

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Washington University School of Medicine·interventional·Posted Sep 9, 2020·Updated Feb 14, 2023

In Brief

A Phase 1 clinical trial evaluating Dapagliflozin and BIOSENSE meters for Pancreas Cancer and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedSep 9, 2020
Enrollment StartFeb 25, 2021
Primary CompletionDec 24, 2021
Study CompletionJan 19, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.8 years ago

Interventions

Dapagliflozindrug

Dapagliflozin will be provided for this trial

BIOSENSE metersdevice

-Being used in this trial to evaluate utility for assessing breath ketones